Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.58 |
| ▸ | CA2 | P00918 | 5/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6272290 | 0.87 | ESR1 (0.47) | CA1CA2ESR2SMN1; SMN2MEN1 | |
| SCHEMBL9419949 | 0.84 | CA1 (0.56) | CA1CA2ESR2MAPTNPC1 | |
| SCHEMBL5663821 | 0.81 | TRPV1 (0.56) | CA1CA2ESR2MAPTNPC1 | |
| SCHEMBL27029419 | 0.81 | CA1 (0.53) | CA1CA2ESR2MAPTNPC1 | |
| SCHEMBL27029434 | 0.81 | CA1 (0.53) | CA1CA2ESR2MAPTNPC1 | |
| SCHEMBL24938412 | 0.81 | MAPT (0.56) | CA1CA2ESR2MAPTNPC1 | |
| SCHEMBL11985689 | 0.81 | MAPT (0.73) | CA1CA2ESR2MAPTNPC1 | |
| SCHEMBL5663408 | 0.80 | CES2 (0.57) | ESR2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9296377 | 0.79 | MAPT (0.50) | CA1CA2ESR2MAPTMEN1 | |
| 4-Methoxybenzoic Acid Ethyl Ester SCHEMBL203475 | 0.79 | CA1 (0.66) | CA1CA2ESR2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | claimed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | claimed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | claimed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | claimed |
| EP-1720840-B1 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-1720840-B1 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2016-02-03 | — | — | EP | disclosed |
| US-8420354-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420354-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7785839-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7785839-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7785839-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1720840-A4 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1720840-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | SZNAIDMAN MARCOS | 2006-02-16 | — | — | US | disclosed |
| WO-2005074654-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | DCTD, AMPD1, DAD1 | CA1 859/4885CA2 3735/4885ESR2 4534/4885 |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | DCTD, AMPD1, DAD1 | CA1 776/4885CA2 3656/4885ESR2 4496/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | CA1 639/4885CA2 1624/4885ESR2 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.